veliparib
Selected indexed studies
- Veliparib for the treatment of solid malignancies. (J Oncol Pharm Pract, 2022) [PMID:35037770]
- Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. (JAMA Oncol, 2024) [PMID:39480453]
- Veliparib‑Induced Toxicity in Cancer Patients: A Systematic Review and Meta‑Analysis. (Cancer Invest, 2024) [PMID:38588003]
_Worker-drafted node — pending editorial review._
Connections
veliparib is a side effect of
Sources
- Veliparib for the treatment of solid malignancies. (2022) pubmed
- Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. (2024) pubmed
- Veliparib‑Induced Toxicity in Cancer Patients: A Systematic Review and Meta‑Analysis. (2024) pubmed
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. (2018) pubmed
- Veliparib: a new therapeutic option in ovarian cancer? (2019) pubmed
- Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. (2022) pubmed
- Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. (2020) pubmed
- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. (2020) pubmed
- Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results. (2025) pubmed
- The efficacy of Veliparib in combination with chemotherapy in the treatment of lung cancer: systematic review and meta-analysis. (2024) pubmed